The group discusses implications of the semaglutide cirrhosis late-breaker and shares what they anticipate might be different one year from now.
MORE >
S3-E34.3 – ILC2022 Looking Back: Early Pemvidutide Results and a Little More on FIB-4
Sunday, July 3, 2022 9:20 AM
Stephen Harrison leads the regular Surfers, Mazen Noureddin and Michelle Long through a discussion of Phase 1 results for pemvidutide, Altimune's dual GLP-1/glucagon agonist for obesity (and presumably NASH), based on his presentation at ILC2022.
MORE >
S3-E34.2 – #ILC2022 Looking Back: Other Thoughts on Resmetirom Presentations
Saturday, July 2, 2022 3:49 PM
After Stephen Harrison shares key elements from two of his resmetirom presentations at #ILC2022, Jörn Schattenberg, Mazen Noureddin and Michelle Long share thoughts and questions about the presentation. After this, Jörn Schattenberg shares key points from his presentation of an assessment of accuracy of FIB-4 in 2,000 biopsy-confirmed patients in the resmetirom trials.
MORE >
S3-E34.1 – #ILC2022 Looking Back: Resmetirom Late-Breaker and Cirrhosis Study
Saturday, July 2, 2022 12:43 PM
Stephen Harrison leads a panel including the regular Surfers, Mazen Noureddin and Michelle Long through key elements of his presentation of the Phase 3 MAESTRO NAFLD-1 study at #ILC2022. He also shares information about an analysis of cirrhotic patients in the open-label cohort of the study.
MORE >
S3-E34 – #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!
Thursday, June 30, 2022 4:13 PM
Michelle Long and Mazen Noureddin join the Surfers (including Stephen Harrison) for a wrap-up of the major stories of #ILC2022. Much of the episode focuses on Nash Drug Development, with side conversations about the value and challenges of relying on FIB-4 or, even worse, ALT in patient screening and diagnosis.
MORE >
S1-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance
Wednesday, June 29, 2022 6:09 PM
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among Type 2 Diabetes Mellitus patients and the value of early screening, particularly in endocrinology clinics, where the percent of patients with NAFLD and NASH fibrosis is double what we find in primary care. NAFLD prevalence […]
MORE >
S3-E33 – Day 4 of ILC2022: Friendly debates about NITs and the Patient Advocate's Perspective
Tuesday, June 28, 2022 9:28 PM
Mazen Noureddin and Ian Rowe join Louise Campbell and Jörn Schattenberg to discuss an important discussion about the roles different NITs will play in the future of NASH diagnosis, treatment and monitoring. Then Louise talks with PBC Foundation CEO Robert Mitchell-Thain about
MORE >
S3-E32 – Days 1 — 3 of ILC 2022: The Value of FIB-4 and In-Person Meetings
Sunday, June 26, 2022 8:13 PM
Michelle Long and Zobair Younossi join the Surfers to discuss the first three days of #ILC2022.
We record Monday afternoons EST, with invites to join sent to all valid requests no later than Monday morning Eastern US time. Our host Roger Green will invite you into the episode to ask your questions and to address your feedback regarding anything and everything in Fatty Liver Disease. Our usual Surfers will also be there each week, every episode.
